Nanexa Shares Jump 114% on $1.3 Billion Novo Nordisk Deal

Nanexa shares surged 114% after the small Swedish drug-delivery company announced a licensing agreement with Novo Nordisk worth up to $1.3 billion. The deal gives Novo Nordisk access to Nanexa's delivery technology platform. For a company of Nanexa's size, a licensing deal of this scale is transformative: it validates the underlying technology and provides a large potential revenue stream tied to milestone payments and royalties rather than upfront cash alone, though the wire report does not break down the payment structure. What is unresolved is how much of the $1.3 billion is guaranteed versus contingent on future regulatory or sales milestones, a detail investors will want before valuing the deal fully.